Fat-free mass

There are 392 papers on fat-free mass in aging research: 117 trials and 212 observational studies in people, 4 in animals, 54 reviews.

Biomarker

392 papers study it637 more mention it92 findings

57 new papers in 30 daysSee all 1,029 papers on fat-free mass

At a glance

Lower fat-free mass is associated with older age in human cohorts, while higher fat-free mass is linked with lower odds of cognitive frailty and better cognition. Human resistance-training trials report increases in fat-free mass, whereas other exercise trials report decreases or no clear effect. A caloric-restriction trial reports a decrease.

92 findings in 78 papers from 1999 to 2026, 14 of them since April 2026

“Short-term changes in HbA1c, insulin, and HOMA-IR were statistically associated with concurrent changes in FFM, MS, and RMR”
Short-Term Associations Between Fat-Free Mass Preservation and Glycaemic Markers During Tirzepatide Therapy: A Secondary Exploratory AnalysisNutrients2026doi:10.3390/nu18071092
  • Human trial117
  • Humans212
  • Animals4
  • In silico1

Interventions

24

Resistance training

upin humans4

4 studies
  1. Resistance training increases fat-free mass in humans (compared with group-based dance).

    Human trialcompared with group-based dance12 weeks

  2. Resistance training increases fat-free mass in humans.

    Human trialwhole body12 weeksmalesn = 39

  3. Resistance training increases fat-free mass in humans (1.0 ± 0.3 kg).

    Human trial12 weeksmalesn = 33

  4. Resistance training increases fat-free mass in humans (experimental group, 24-week program).

    Human trialexperimental group, 24-week programthree times per week24 weeksfemalesn = 69

  5. Resistance training increases fat-free mass in humans.

    Review

More on Resistance training

GLP-1 receptor agonists

downin humans3downin reviews1−40% total weight loss from ffm

4 studies
  1. GLP-1 receptor agonists are linked with lower fat-free mass in humans (1.8% reduction at 6 months (95% CI 1.3%-2.4%); 3.3% at 24 months).

    Humansrelative change at 6 months, adjusted for age, sex, race, baseline BMI, diabetes history and treatment year6 monthsn = 1,809

  2. GLP-1 receptor agonists decrease fat-free mass (~25% of weight loss).

    Review

  3. GLP-1 receptor agonists decrease fat-free mass in humans (up to 40% of total weight loss from FFM).

    Review

  4. GLP-1 receptor agonists decrease fat-free mass in humans (percentage of total weight lost as fat-free mass, measured by DXA) (20–40% of total weight lost as fat-free mass).

    Reviewpercentage of total weight lost as fat-free mass, measured by DXA

More on GLP-1 receptor agonists

Exercise

upin humans2no changein humans1downin humans1

4 studies
  1. Exercise showed no clear effect on fat-free mass in humans.

    Human trial6 monthsn = 119

  2. Exercise decreases fat-free mass in humans (-2.8 kg (95% CI: -4.1; -1.6)).

    Human trial10 weeksn = 24

  3. Exercise increases fat-free mass in humans (-4.9 vs. -7.9 kg).

    Human trialskeletal muscle6 monthsfemalesn = 80

  4. Exercise increases fat-free mass in humans during calorie restriction (MD = +0.87 kg, 95% CI: +0.59, +1.16 kg).

    Reviewduring calorie restrictionn = 1,455

More on Exercise

Bariatric surgery

downin humans4

4 studies
  1. Bariatric surgery is linked with lower fat-free mass in humans (FFM from 61.1 ± 11.9 to 50.1 ± 7.0 kg (p < 0.001)).

    Humans12 monthsn = 179

  2. Bariatric surgery is linked with lower fat-free mass in humans (7.8% reduction at 6 months (95% CI 7.2%-8.4%); 11.7% at 24 months).

    Humansrelative change at 6 months, adjusted for age, sex, race, baseline BMI, diabetes history and treatment year6 monthsn = 1,257

  3. Bariatric surgery is linked with lower fat-free mass in humans.

    Humansn = 100

  4. Bariatric surgery decreases fat-free mass in humans (-8.23 kg [95%CI -10.74; -5.73]).

    Review12-month

More on Bariatric surgery

Semaglutide

downin humans2

2 studies
  1. Semaglutide is linked with lower fat-free mass in humans within semaglutide group (FFM 53.8 to 52.7 kg; p < 0.001).

    Humanswithin semaglutide group12 months

  2. Semaglutide decreases fat-free mass in humans (compared with placebo in type 2 diabetes) (MD -1.68 (95% CI -2.84 to -0.52)).

    Reviewcompared with placebo in type 2 diabetes

More on Semaglutide

Creatine

no changein humans1upin humans1

2 studies
  1. Creatine showed no clear effect on fat-free mass in humans.

    Human trialn = 20

  2. Creatine increases fat-free mass in humans during resistance training, in comparison with Pro and Pro/Col.

    Human trialduring resistance training, in comparison with Pro and Pro/Col12 wkn = 49

More on Creatine

Sukubara training system

upin humans1

1 study
  1. Sukubara training system increases fat-free mass in humans (0.5 ± 0.5 vs. −0.1 ± 0.5 kg).

    Human trial12 weeksn = 15

  2. Sukubara training system increases fat-free mass in humans (0.5 ± 0.5 vs. -0.1 ± 0.5 kg).

    Human trial12-weekn = 15

More on Sukubara training system

Bioelectrical impedance analysis

no changein humans1

1 study
  1. Bioelectrical impedance analysis showed no clear effect on fat-free mass in humans (type 2 diabetes mellitus) (bias +0.82 kg (95% CI −0.69 to +2.34)).

    Reviewtype 2 diabetes mellitusn = 646

More on Bioelectrical impedance analysis

Synbiotics

no changein humans1

1 study
  1. Synbiotics showed no clear effect on fat-free mass in humans (perimenopausal women with migraine and intestinal dysbiosis).

    Human trialperimenopausal women with migraine and intestinal dysbiosis6 monthsfemales

More on Synbiotics

Incretin-based therapy

downin humans1

1 study
  1. Incretin-based therapy decreases fat-free mass in incretin-based trials (-6.8% to -10.9%; 33%-38% of total weight loss).

    Reviewin incretin-based trials

More on Incretin-based therapy

Gochujang

upin humans1

1 study
  1. Gochujang increases fat-free mass in humans (compared with baseline and other groups as reported).

    Human trialcompared with baseline and other groups as reportedlow-Gochujang8 weeksfemales

More on Gochujang

Low-calorie diet

downin humans1

1 study
  1. Low-calorie diet decreases fat-free mass in humans (combined with tirzepatide; compared with low-energy ketogenic therapy) (significantly greater FFM reduction than TZP+LEKT (p = 0.0388)).

    Human trialcombined with tirzepatide; compared with low-energy ketogenic therapy12 weeks

More on Low-calorie diet

Caloric restriction

downin humans1

1 study
  1. Caloric restriction decreases fat-free mass in humans (−4.29% ± 1.31 vs. −0.50% ± 0.82).

    Human trial12 weeksn = 60

More on Caloric restriction

Time-restricted feeding

downin humans1

1 study
  1. Time-restricted feeding decreases fat-free mass in young adults with overweight or obesity.

    Human trialin young adults with overweight or obesityeight weeksn = 16

More on Time-restricted feeding

Combined exercise and dietary intervention

no changein humans1

1 study
  1. Combined exercise and dietary intervention showed no clear effect on fat-free mass in patients with ovarian cancer during and after chemotherapy (β = -0.5 kg, 95% CI -3.2 to 2.1).

    Human trialin patients with ovarian cancer during and after chemotherapyfemalesn = 81

More on Combined exercise and dietary intervention

All 24

Effects

2

Cognitive function

upin humans1OR 1.081

1 study
  1. Fat-free mass is linked with better cognitive function in humans (OR 1.081, 95% CI 1.045-1.119).

    Humans

Isotope dilution space ratio

no changein humans1

1 study
  1. Fat-free mass was not clearly linked with isotope dilution space ratio in humans.

    Humans

More on Isotope dilution space ratio

Upstream

2

Age

downin humans2

2 studies
  1. Age is linked with lower fat-free mass in humans.

    Humansmales

  2. Age is linked with lower fat-free mass in humans.

    Humansn = 3,451

Chronic obstructive pulmonary disease

downin humans1

1 study
  1. Chronic obstructive pulmonary disease is linked with lower fat-free mass in humans (patients with COPD) (-1173 [-1527/-820] g).

    Humanspatients with COPD2 yearsn = 205

More on Chronic obstructive pulmonary disease

Associations

42

Bioelectrical impedance analysis

upin humans2

2 studies
  1. Bioelectrical impedance analysis is associated with fat-free mass in humans (mean difference 0.52 kg).

    Humansfemalesn = 79

  2. Bioelectrical impedance analysis is associated with fat-free mass in humans (compared with anthropometric tools in 14 centenarians in Italy).

    Reviewcompared with anthropometric tools in 14 centenarians in Italyn = 14

More on Bioelectrical impedance analysis

Resting energy expenditure

upin humans2

2 studies
  1. Fat-free mass is associated with resting energy expenditure in adapted patients with obesity.

    Humansin adapted patients with obesityn = 23

  2. Fat-free mass is associated with resting energy expenditure in humans.

    Humansn = 72

More on Resting energy expenditure

Sarcopenia

downin humans1upin humans1

2 studies
  1. Sarcopenia is associated with fat-free mass in humans (compared to control group).

    Humanscompared to control group

  2. Sarcopenia is associated with fat-free mass in humans (nursing home residents).

    Humansnursing home residentsn = 66

More on Sarcopenia

Age

downin humans2

2 studies
  1. age is associated with fat-free mass in humans (adjusted for covariates; changes from age 60 to 90 years) (-2.8 kg (women), -3.5 kg (men)).

    Humansadjusted for covariates; changes from age 60 to 90 yearsn = 401

  2. Age is associated with fat-free mass in humans (r = -0.25).

    Humansmalesn = 102

More on Age

Hand grip strength

upin humans1

1 study
  1. Fat-free mass predicts hand grip strength in humans (multivariate analysis).

    Humansmultivariate analysisn = 109

  2. Fat-free mass is associated with hand grip strength in humans.

    Humansn = 109

Total mortality

downin humans1HR 0.96

1 study
  1. Fat-free mass is associated with total mortality in humans (full cohort) (HR 0.96, 95% CI 0.93–1.00).

    Humansfull cohortfemalesn = 3,439

10-year ASCVD risk

downin humans1

1 study
  1. Fat-free mass is associated with 10-year ASCVD risk in humans (Sex-adjusted linear regression).

    HumansSex-adjusted linear regressionn = 761

More on 10-year ASCVD risk

HbA1c

upin humans1

1 study
  1. Fat-free mass is associated with HbA1c in humans (total FFM and FFM/height2 tertiles).

    Humanstotal FFM and FFM/height2 tertilesn = 59,269

    Fat-free mass links to metabolic health varied with deep belly fat

    The Journal of clinical endocrinology and metabolism

More on HbA1c

Metabolic syndrome

upin humans1

1 study
  1. Fat-free mass is associated with metabolic syndrome in humans (total FFM and FFM/height2 tertiles).

    Humanstotal FFM and FFM/height2 tertilesn = 59,269

    Fat-free mass links to metabolic health varied with deep belly fat

    The Journal of clinical endocrinology and metabolism

More on Metabolic syndrome

Migraine disability

downin humans1

1 study
  1. Fat-free mass is associated with migraine disability in humans (perimenopausal women with migraine and intestinal dysbiosis) (rho = −0.667, p = 0.009).

    Human trialperimenopausal women with migraine and intestinal dysbiosisfemalesn = 14

HbA1c, insulin and HOMA-IR

mixedin humans1

1 study
  1. Fat-free mass is associated with HbA1c, insulin and HOMA-IR in humans.

    Human trialduring tirzepatide therapy; concurrent changes in muscle strength and resting metabolic rate12 weeks

More on HbA1c, insulin and HOMA-IR

All 42

Funding

1 grant since 2021

National Institute of Diabetes and Digestive and Kidney Diseases$648K

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Human studies associate fat-free mass with metabolic syndrome, HbA1c, eGFR and a prudent dietary pattern. A human-trial preprint links higher fat-free mass to less migraine disability in perimenopausal women with migraine and intestinal dysbiosis, but reports no change in fat-free mass after six months of prebiotics plus probiotics in this group.

  2. Summary written from the findings.

Latest

Dec 2025: 18Jan 2026: 26Feb 2026: 24Mar 2026: 30Apr 2026: 14May 2026: 16Jun 2026: 15Jul 2026: 15Aug 2026: 18Sep 2026: 22Oct 2026: 41Nov 2026: 26265 papers in 12 months

See all 1,029 papers on fat-free mass